Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer

Urology

Volumn 57, Issue 1, 2001, Pages 102-107

  Shu, Hui Kuo G ^a   Lee, Terry T ^a   Vigneault, Eric ^a   Xia, Ping ^a   Pickett, Barby ^a   Phillips, Theodore L ^a   Roach III, Mack ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; UROGENITAL TRACT DISEASE;

AGED; ANALYSIS OF VARIANCE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; MALE; MALE UROGENITAL DISEASES; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES;

EID: 0035156326     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00890-6     Document Type: Article

References (27)

1. Cancer statistics, 1998
2. Cancer surveillance series; interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
3. Patterns of care outcome studies; results of the national practice in adenocarcinoma of the prostate
4. The effect of dose on local control of prostate cancer
5. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate; analysis of RTOG studies 7506 and 7706
6. Late effects after radiotherapy for prostate cancer in a randomized dose-response study; results of a self-assessment questionnaire
7. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer; a randomised trial
8. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer
9. Dose escalation with 3D conformal treatment; five year outcomes, treatment optimization, and future directions
10. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
11. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406
12. Rectal bleeding after conformal 3D treatment of prostate cancer; time to occurrence, response to treatment and duration of morbidity
13. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma
14. 3) spatial resolution
15. Prostate cancer; localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study
16. Sextant localization of prostate cancer; comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopy imaging with step section histology
17. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy
18. Comparison of intensity modulated treatment plans for multiple dominant intra-prostatic lesions of prostate cancer
19. Optimization of the oblique angles in the treatment of prostate cancer during six-field conformal radiotherapy
20. The value of nonuniform margins for six-field conformal irradiation of localized prostate cancer
21. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer
22. Three dimensional conformal radiotherapy for the treatment of prostate cancer; low risk of chronic rectal morbidity observed in a large series of patients
23. Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales
24. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate
25. External beam radiotherapy dose response of prostate cancer
26. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy
27. The 'critical volume tolerance method' for estimating the limits of dose escalation during three-dimensional conformal radiotherapy for prostate cancer